Posts

Novartis drops phase 2 radioligand therapy, but CEO’s commitment to the modality unchanged

on

US Physicians Cautious About AI‑Driven Home Testing

on

FDA Releases 14 New Drug Rejection Letters After 3‑Month Pause in Transparency Policy

on

ADC Therapeutics shares sink over 50% after Phase 3 Zynlonta trial shows more deaths than standard therapy

on

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

on

Utah AI prescription pilot data strengthens case for AI‑assisted Rx tools

on

CDER chief Høeg, skeptic of vaccines and antidepressants, is fired in high-level FDA shakeup

on

Gilead Cancels Midstage HIV Trial as FDA Clinical Hold Remains Intact

on

AstraZeneca's In Vivo CAR-T ESO-T01 Shows Promise in Multiple Myeloma with Remissions but One Death in China Trial

on

BioMarin and Voxzogo: Recent Clinical Developments and Safety Information

on

Eli Lilly Warns of Dangerous Impurity in Compounded Tirzepatide with Vitamin B12

on

Ipsen Withdraws Cancer Drug Tazverik from Market Due to Secondary Blood Cancer Risks

on

Sarepta Therapeutics CEO Doug Ingram to Step Down by End of 2026 Amid Controversial Tenure

on

FDA Delays Reviews for Eli Lilly, Sanofi, and Others in New Priority Voucher Program Due to Safety and Efficacy Concerns

on

FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations

on

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025

on

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

on

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

on

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

on

Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic

on